Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;3(4):829-832.
doi: 10.3892/mco.2015.545. Epub 2015 Apr 16.

Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas

Amir Sonnenblick  1 , Feras Eleyan  1 , Tamar Peretz  1 , Inna Ospovat  2 , Ofer Merimsky  2 , Tamar Sella  3 , Nili Peylan-Ramu  1 , Daniela Katz  1
Affiliations

Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas

Amir Sonnenblick et al. Mol Clin Oncol. 2015 Jul.

Abstract

A limited number of chemotherapeutic agents have been found to be active against advanced soft-tissue sarcomas (STSs), particularly sarcomas that have progressed following doxorubicin treatment. The aim of this retrospective study was to determine the response to treatment with gemcitabine plus paclitaxel in patients with STSs. Data were collected on all patients with advanced non-resectable STS who were treated with a fixed dose 700 mg/m2 gemcitabine in combination with 70 mg/m2 paclitaxel on days 1 and 8 every 3 weeks. A total of 30 patients were included, with a median age of 56.4 years (range, 40-70 years). The gemcitabine/paclitaxel combination was well tolerated, with an overall response in 27% and a clinical benefit in 57% of the patients. The median progression-free survival was 6.1 months and the overall survival was 14.3 months. In conclusion, gemcitabine plus paclitaxel was found to be tolerable and effective in patients with advanced STSs.

Keywords: gemcitabine; paclitaxel; soft-tissue sarcomas; stage 4.

PubMed Disclaimer

References

    1. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317–321. doi: 10.1097/00000421-199806000-00025. - DOI - PubMed
    1. Lorigan P, Verweij J, Papai Z, et al. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25:3144–3150. doi: 10.1200/JCO.2006.09.7717. - DOI - PubMed
    1. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study) Oncologist. 2012;17:1213–1220. doi: 10.1634/theoncologist.2011-0467. - DOI - PMC - PubMed
    1. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 (corrected) J Clin Oncol. 2007;25:2755–2763. doi: 10.1200/JCO.2006.10.4117. - DOI - PubMed
    1. Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol. 2000;45:177–181. doi: 10.1007/s002800050027. - DOI - PubMed